Free tool
FAERS Monitor: Sodium Nitrite
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 203922 or its brand name (Sodium Nitrite, Sodium Nitrite). Reports on generic versions are filed under their own applications.
Reports
57
Serious
56
98% of reports
Hospitalization
23
Death reported
39
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- completed suicide25
- methaemoglobinaemia15
- toxicity to various agents13
- overdose8
- suicide attempt7
- cardiac arrest6
- cyanosis6
- drug ineffective6
- hypoxia5
- anoxia4
- brain oedema4
- cardiac failure acute3
- cardio-respiratory arrest3
- coma3
- pulmonary haemorrhage3
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2006 | 1 |
| 2012 | 1 |
| 2020 | 4 |
| 2021 | 8 |
| 2022 | 11 |
| 2023 | 8 |
| 2024 | 4 |
| 2025 | 15 |
| 2026 | 5 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,102 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| anoxiaSignal | 4 | 4245.6 | 1640.6 | 12,848 |
| methaemoglobinaemiaSignal | 15 | 2406.8 | 1555.8 | 33,492 |
| cardiac failure acuteSignal | 3 | 166.3 | 55.2 | 341 |
| pulmonary haemorrhageSignal | 3 | 141.5 | 47.0 | 290 |
| cyanosisSignal | 6 | 140.8 | 66.1 | 699 |
| brain oedemaSignal | 4 | 117.0 | 45.5 | 351 |
| completed suicideSignal | 25 | 110.7 | 82.5 | 2,620 |
| hypoxiaSignal | 5 | 52.4 | 22.7 | 204 |
| suicide attemptSignal | 7 | 42.6 | 21.3 | 245 |
| toxicity to various agentsSignal | 13 | 28.4 | 17.6 | 320 |
| cardiac arrestSignal | 6 | 26.8 | 12.6 | 125 |
| cardio-respiratory arrestSignal | 3 | 26.5 | 8.8 | 50 |
| comaSignal | 3 | 23.2 | 7.7 | 44 |
| overdoseSignal | 8 | 13.7 | 7.2 | 83 |
| drug ineffective | 6 | 1.7 | 0.8 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.